Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry

NCT06769412 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT06769412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06769412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
July 1, 2025
Completion date
September 1, 2025
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vasculitis